Bristol Myers Squibb (CELG-RI) Enterprise Value (2009 - 2026)
Bristol Myers Squibb (CELG-RI) reported Enterprise Value of -$10.5 billion for Q1 2026, up 10.84% year-over-year from -$9.4 billion in Q1 2025, and up 1.77% quarter-over-quarter from -$10.6 billion in Q4 2025.
Bristol Myers Squibb (CELG-RI) Enterprise Value (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 18 years of Enterprise Value data on file, last reported at -$10.5 billion in Q1 2026.
- Enterprise Value for Q1 2026 came in at -$10.5 billion, up 10.84% year-over-year; the trailing twelve-month figure through Mar 2026 was -$10.5 billion (up 10.84% YoY), and the FY2025 annual result was -$10.6 billion, up 1.54% from the prior year.
- Enterprise Value advanced to -$10.5 billion in Q1 2026 per CELG-RI's latest filing, from -$10.6 billion in the prior quarter.
- Over five years, Enterprise Value peaked at -$6.6 billion in Q2 2024 and troughed at -$16.5 billion in Q3 2025.
- A 5-year average of -$10.7 billion and a median of -$10.5 billion in 2026 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2025: Enterprise Value soared 45.61% in 2022, then sank 105.32% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$9.2 billion in 2022, then slumped by 32.94% to -$12.2 billion in 2023, then increased by 11.61% to -$10.8 billion in 2024, then advanced by 1.54% to -$10.6 billion in 2025, then grew by 1.77% to -$10.5 billion in 2026.
- Business Quant data shows CELG-RI's Enterprise Value at -$10.5 billion in Q1 2026, -$10.6 billion in Q4 2025, and -$16.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -4.96 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | -5.28 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | -22.05 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -9.35 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -5.65 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | -12.04 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | -7.73 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -12.77 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -10.45 Bn |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn | -10.45 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.45 Bn |
| Dec 31, 2025 | -10.64 Bn |
| Sep 30, 2025 | -16.45 Bn |
| Jun 30, 2025 | -13.55 Bn |
| Mar 31, 2025 | -11.72 Bn |
| Dec 31, 2024 | -10.81 Bn |
| Sep 30, 2024 | -8.04 Bn |
| Jun 30, 2024 | -6.60 Bn |
| Mar 31, 2024 | -9.61 Bn |
| Dec 31, 2023 | -12.23 Bn |
| Sep 30, 2023 | -7.62 Bn |
| Jun 30, 2023 | -8.67 Bn |
| Mar 31, 2023 | -9.21 Bn |
| Dec 31, 2022 | -9.20 Bn |
| Sep 30, 2022 | -8.96 Bn |
| Jun 30, 2022 | -13.17 Bn |
| Mar 31, 2022 | -14.90 Bn |
| Dec 31, 2021 | -16.91 Bn |
| Sep 30, 2021 | -15.59 Bn |
| Jun 30, 2021 | -12.90 Bn |